<DOC>
	<DOCNO>NCT00002087</DOCNO>
	<brief_summary>To investigate safety tolerance increase number infusion per week alvircept sudotox ( sCD4-PE40 ; soluble CD4-Pseudomonas exotoxin ) fix dose administer HIV-1-infected individual . To investigate effect sCD4-PE40 follow parameter : T lymphocyte subset , plasma HIV RNA cellular HIV proviral DNA PBMC CD4 cell , p24 level , serum beta-2 microglobulin , neopterin level .</brief_summary>
	<brief_title>Safety , Tolerance , Efficacy Pharmacokinetics Multiple Doses sCD4-PE40 Treatment HIV-Infected Individuals</brief_title>
	<detailed_description />
	<mesh_term>HIV Infections</mesh_term>
	<criteria>Inclusion Criteria Patients must : HIV positivity confirm Western blot . CD4 count 100 500 cells/mm3 morning draw within 3 week prior study entry . Exclusion Criteria Coexisting Condition : Patients follow symptoms condition exclude : Concurrent neoplasm basal cell carcinoma skin , situ carcinoma cervix , nondisseminated Kaposi 's sarcoma . Hemophilia clot disorder . Major organ allograft . Significant cardiac , hepatic , renal , CNS disease . Prior Medication : Excluded : Antiretroviral agent within 2 month prior study entry . Known antiHIV medication within 60 day prior study entry . Prior immunomodulators ( e.g. , systemic steroid , interferon , interleukin ) chemotherapy . Prior Treatment : Excluded : Prior radiation therapy . Active substance abuse .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>April 1994</verification_date>
	<keyword>Recombinant Proteins</keyword>
	<keyword>Acquired Immunodeficiency Syndrome</keyword>
	<keyword>Antigens , CD4</keyword>
	<keyword>AIDS-Related Complex</keyword>
</DOC>